¶ Dysautonomia and Non-Motor Complications in Parkinson's Disease — MDS 2026
The MDS 2026 Congress features extensive programming on autonomic dysfunction and non-motor complications in Parkinson's disease, reflecting the growing recognition that these symptoms significantly impact quality of life and often precede motor signs by years or decades.
¶ Autonomic Dysfunction in PD
¶ Cardiovascular Dysregulation
¶ Orthostatic Hypotension
Orthostatic hypotension (OH) affects 30-50% of PD patients and represents a major cause of morbidity[1]:
| Feature | Details |
|---|---|
| Definition | ≥20 mmHg systolic or ≥10 mmHg diastolic drop within 3 minutes of standing |
| Prevalence | 30-50% of PD patients |
| Pathogenesis | Central autonomic network degeneration, norepinephrine deficiency |
| Symptoms | Lightheadedness, syncope, falls, postprandial worsening |
| Management | Volume expansion, compression garments, midodrine, droxidopa |
MDS 2026 Key Insights:
- OH may be the presenting symptom in up to 10% of PD patients
- Supine hypertension complicates management in 50% of OH patients
- Baroreflex failure precedes cardiac sympathetic denervation
- Non-dopaminergic medications (midodrine, droxidopa) preferred to avoid motor worsening
¶ Supine Hypertension
- Present in 50% of PD patients with OH
- Contribute to nocturnal supine renal sodium loss
- Management: bedtime clonidine, bedtime losartan, elevate head of bed
¶ Heart Rate Variability
- Reduced HRV predicts faster disease progression
- Cardiac sympathetic denervation measured via 123I-MIBG scintigraphy
- Correlates with Braak stage 1-2 (enteric/medullary involvement)
¶ Gastrointestinal Dysfunction
¶ Constipation
Constipation affects 60-80% of PD patients and may precede motor symptoms by decades[2]:
| Aspect | Details |
|---|---|
| Prevalence | 60-80% |
| Rome Criteria |  bowel movements/week, straining, incomplete evacuation |
| Pathogenesis | Alpha-synuclein deposition in ENS, Lewy bodies in myenteric plexus |
| Colon transit time | Delayed by 2-3x normal |
| Treatment | Fiber, osmotic laxatives, prokinetics, lubiprostone |
Braak Hypothesis Connection:
- Enteric nervous system (ENS) is among the earliest sites of α-syn pathology
- α-Synuclein in submucosal and myenteric neurons precedes CNS involvement
- GI dysfunction may provide biomarkers for prodromal PD detection
¶ Gastroparesis
- Delayed gastric emptying in 30-50%
- Contributes to levodopa malabsorption ("delayed-on" phenomenon)
- Management: domperidone, erythromycin, dietary modifications
¶ Sialorrhea (Excessive Drooling)
- Affects 30-50% of PD patients
- Due to reduced swallow frequency, not increased production
- Treatment: anticholinergics, botulinum toxin to salivary glands
¶ Urinary Dysfunction
Urinary dysfunction occurs in 45-70% of PD patients, primarily as detrusor overactivity[3]:
| Type | Prevalence | Mechanism |
|---|---|---|
| Urgency/Frequency | 45-70% | Detrusor overactivity from basal ganglia inhibition loss |
| Nocturia | 60-80% | Combination of OH, sleep fragmentation, detrusor overactivity |
| Incomplete emptying | 20-30% | Urethral sphincter bradykinesia |
Management:
- Anticholinergics: solifenacin, tolterodine (watch cognitive side effects)
- Beta-3 agonists: mirabegron
- Intermittent catheterization for retention
¶ Sexual Dysfunction
- Erectile dysfunction: 50-70% of male PD patients
- Reduced libido: 40-60%
- Contributors: autonomic dysfunction, depression, medication effects
¶ Sudomotor Dysfunction
- Anhidrosis or hyperhidrosis in 30-50%
- May present as patchy sweating patterns
- Correlates with disease severity
¶ Sleep Disorders in PD
¶ REM Sleep Behavior Disorder
RBD affects 50-60% of PD patients and is a strong predictor of synucleinopathy[4]:
| Feature | Details |
|---|---|
| Prevalence | 50-60% in established PD |
| Core criteria | REM sleep without atonia, dream enactment behaviors |
| Polysomnography | REM sleep without atonia + ≥5/80% tonic chin EMG activity |
| Disease association | 80-90% develop parkinsonism or dementia within 10-15 years |
Pathophysiology:
- Subcoeruleus nucleus degeneration (PPTg, SLD)
- Loss of glycinergic/GABAergic inhibition of motor neurons
- Earlier onset RBD predicts more aggressive α-syn pathology
Treatment:
- Clonazepam: 0.25-1.0 mg HS (most effective)
- Melatonin: 3-12 mg HS (better tolerated)
- Bed safety measures
¶ Insomnia
- Prevalence: 60-90%
- Causes: nocturnal akinesia, depression, medication effects, RBD
- Management: sleep hygiene, timed levodopa dosing, cognitive behavioral therapy
¶ Excessive Daytime Sleepiness
- Prevalence: 30-50%
- Evaluation: Epworth Sleepiness Scale, MSLT
- Contributors: medications (dopaminergics, antidepressants), nocturnal sleep disruption
¶ Restless Legs Syndrome
- Prevalence: 15-20% (vs 5-10% in general population)
- Improvement with dopaminergic therapy
- Differential diagnosis from akathisia
¶ Neuropsychiatric Complications
¶ Depression
Depression affects up to 50% of PD patients and is the most common neuropsychiatric symptom[5]:
| Feature | Details |
|---|---|
| Prevalence | 30-50% |
| Timing | Can precede motor symptoms by years |
| Presentation | Anhedonia, guilt, apathy vs somatic symptoms |
| Treatment | SSRIs (citalopram, sertraline), SNRIs, CBT |
MDS 2026 Updates:
- Depression correlates with dorsal raphe and locus coeruleus pathology
- Neurochemical basis: serotonin and norepinephrine depletion
- Tricyclic antidepressants may worsen OH
¶ Anxiety
- Prevalence: 25-40%
- Often co-occurs with depression
- Can manifest as panic attacks, generalized anxiety, or social phobia
- Related to "off" periods and motor fluctuations
¶ Psychosis
Parkinson disease psychosis (PDP) affects 20-40% of patients[@pd psychosis2025]:
| Feature | Details |
|---|---|
| Prevalence | 20-40% (all parkinsonism), 50-60% (PDD) |
| Core symptoms | Visual hallucinations, delusions, misidentifications |
| Risk factors | Age, disease duration, cognitive impairment, dopaminergic meds |
| Pathology | Lewy body pathology in ventral temporal cortex, limbic system |
Management Approach:
- Reduce antiparkinsonian medications (gradual, prioritize dopaminergic)
- Pimavanserin (FDA-approved for PDP): 5-HT2A inverse agonist
- Quetiapine: first-line off-label (sedation, metabolic effects)
- Clozapine: most effective but requires weekly WBC monitoring
¶ Apathy
- Prevalence: 30-50%
- Distinct from depression (anhedonia key differential)
- Associated with frontal lobe dysfunction
- Treatment: dopaminergic stimulation, behavioral interventions
¶ Impulse Control Disorders
ICD affects 10-15% of PD patients on dopaminergic therapy[6]:
| Disorder | Features |
|---|---|
| Pathological gambling | Risk-taking behaviors, financial losses |
| Compulsive shopping | Excessive, unplanned purchases |
| Binge eating | Weight gain, metabolic complications |
| Hypersexuality | Inappropriate sexual behaviors |
Risk Factors:
- Dopamine agonist use (pramipexole, ropinirole > rotigotine)
- Male sex
- Young onset
- Personal/family history of OCD or addiction
Management:
- Reduce or discontinue dopamine agonists
- Consider naltrexone (off-label)
- Behavioral therapy
¶ Hallucinations
- Visual hallucinations most common (80-90% of psychotic episodes)
- Often insight-preserved ("les hallucinations")
- Typically begin with minor hallucinations (passage, presence)
- Progress to fully formed visual hallucinations
¶ Cognitive Impairment
¶ Mild Cognitive Impairment in PD
- Prevalence: 20-50%
- Types: executive, attention, memory, visuospatial
- Progression: 50-80% develop dementia over disease course
- Biomarkers: reduced CSF Aβ42, elevated tau, cortical Lewy bodies
¶ Parkinson's Disease Dementia
| Feature | Details |
|---|---|
| Prevalence | 30-80% (duration-dependent) |
| Diagnostic criteria | 1 year rule (PDD vs DLB) |
| Core symptoms | Executive dysfunction, attentional fluctuations, visual hallucinations |
| Progression | Median 4-5 years from PDD onset to nursing home |
Treatment:
- Cholinesterase inhibitors: rivastigmine (FDA-approved), donepezil
- Memantine: modest benefits
- Avoid anticholinergics, benzodiazepines
¶ Fatigue
Fatigue affects 40-70% of PD patients and is among the most disabling non-motor symptoms[7]:
| Aspect | Details |
|---|---|
| Prevalence | 40-70% |
| Types | Physical, mental, psychological |
| Relationship | Correlates with depression, sleep disorders, disease severity |
| Treatment | Exercise, sleep optimization, modafinil (off-label), caffeine |
¶ Pain
Pain affects 40-60% of PD patients:
| Type | Description |
|---|---|
| Musculoskeletal | Rigidity, stiffness, arthritic pain |
| Radicular | Nerve root compression |
| Dystonic | OFF-period cramping, foot dystonia |
| Central | Burning, dysesthetic pain |
| Akathitic | Restless discomfort |
¶ Assessment Tools
¶ Non-Motor Symptoms Scale (NMSS)
- 30 items across 9 domains
- Validated in PD populations
- Used in clinical trials
¶ Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
- Comprehensive assessment of non-motor symptoms
- Excellent psychometric properties
¶ SCOPA-AUT
- 25 items covering autonomic domains
- Validated for PD
¶ PDSS-2 (Parkinson's Disease Sleep Scale-2)
- 15 items assessing sleep quality
¶ Management Principles
- Screen systematically — Use validated tools at each visit
- Treat underlying causes — Optimize dopaminergic therapy, address sleep
- Pharmacologic intervention — Symptom-specific, avoid interactions
- Non-pharmacologic — Lifestyle modifications, exercise, therapy
- Multidisciplinary care — Neurology, psychiatry, sleep medicine, urology, GI
¶ Cross-Links
- Parkinson's Disease
- Autonomic Nervous System
- Alpha-Synuclein
- REM Sleep Behavior Disorder
- Parkinson's Disease Dementia
- Gut-Brain Axis
- Central Autonomic Network
- Non-Motor Symptoms in PD — MDS 2026
¶ References
¶ Additional references
Orthostatic hypotension in Parkinson disease. Neurology. 2024. ↩︎
Gastrointestinal dysfunction in Parkinson disease. Nature Reviews Gastroenterology & Hepatology. 2024. ↩︎
Urinary dysfunction in Parkinson disease. Parkinsonism and Related Disorders. 2024. ↩︎
REM sleep behavior disorder in Parkinson disease. Movement Disorders. 2025. ↩︎
Depression in Parkinson disease. Movement Disorders. 2024. ↩︎
Impulse control disorders in Parkinson disease. Lancet Neurology. 2024. ↩︎
Fatigue in Parkinson disease. Journal of Parkinson's Disease. 2025. ↩︎